Some new targeted drugs have been used for the treatment of high‐risk MDS, such as IDH1 inhibitor,38 Bcl2 inhibitor,39 XPO1 inhibitor,40 anti‐CD47 antibody,41 anti‐PD‐1antibody,42 et al., combined with azacytidine have shown good efficacy. Here, BCL2 is linked to myelodysplastic syndrome.